LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Cowie, Martin R.; Simon, Marcus; Klein, Liviu; Thokala, Praveen (2017)
Publisher: John Wiley & Sons, Ltd
Journal: European Journal of Heart Failure
Languages: English
Types: Article
Subjects: Heart failure, Research Article, Telemonitoring, Research Articles, Cost?effectiveness, Pulmonary artery pressure monitoring, Cardiac Devices
Abstract Aims Heart failure (HF) treatment guided by physicians with access to real?time pressure measurement from a wireless implantable pulmonary artery pressure (PAP) sensor (CardioMEMS), has previously been shown to reduce HF?related hospital admissions in the CHAMPION trial. However, uncertainty remains regarding the value of CardioMEMS in European health systems where healthcare costs are significantly lower than in the USA. Methods and results A Markov model was developed to estimate the cost?effectiveness of PAP?guided treatment of HF using the CardioMEMS? HF system compared with usual care. Cost?effectiveness was measured as the incremental cost per quality?adjusted life year (QALY) gained. In the base case analysis over a time horizon of 10 years, PAP?guided HF therapy increased cost compared with usual care by ?10 916 (?14 030). QALYs per patient for usual care and PAP?guided patients were 2.57 and 3.14, respectively, reflecting an increase of 0.57 QALYs with PAP?guided treatment. The resultant incremental cost?effectiveness ratio (ICER) is ?19 274 (?24 772) per QALY gained. The base case analysis did not include staff time, due to a lack of data concerning this variable. Running the model with estimated staff time included resulted in an increased ICER of between ?22 342 and ?25 464 per QALY gained (?28 709?32 721). Conclusion The analysis indicates that integrating wireless PAP monitoring into the management of UK HF patients is likely to be a cost?effective addition to the HF treatment pathway for appropriate patients.

Share - Bookmark

Cite this article